Ultime notizie per Piper Sandler (NYSE:PIPR) Azioni

PIPER SANDLER COS

Piper Sandler

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.

Wall Street Braces for More Uncertainty

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

PAYO

PIPR

Payoneer, KKR e Piper Sandler: l&#39;RSI segnala eccesso di vendite, ma è davvero il momento di puntare su questi titoli del settore finanziario?

3 azioni finanziarie che potrebbero salire dopo il recente sell-off

Piper Sandler Cos

21Shares, one of the largest issuers of <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43742669/a-dogecoin-etf-approval-in-2025-is-becoming-increasingly-likely-polymarket-traders-speculate">crypto exchange-traded products</a> (ETPs), has officially launched the 21Shares Dogecoin ETP, the first Dogecoin-backed product endorsed by the Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) Foundation.
What Happened: The product went live today, with <a href="https://www.21shares.com/en-eu/product/doge">listing</a> on Swiss exchanges under the ticker DOGE.
The Dogecoin ETP offers exposure to the sixth-largest cryptocurrency by market capitalization, which closed 2024 valued at $46 billion—on par with legacy brands like General Motors.
The ETP enables both institutional and retail investors to gain direct access to Dogecoin through their bank or brokerage accounts, without needing to handle digital wallets or private keys.
"In partnership with House of Doge, we're excited to introduce the only Dogecoin ETP endorsed by the Dogecoin Foundation," 21Shares announced in a <a href="https://x.com/21Shares/status/1909876206020837776">statement</a> on social media. "Here's to the meme that made it."
The product has an annual fee of 2.5%, a net asset value of $5.00 per unit, and is not currently eligible for lending. 
The initial assets under management total $1.2 million, with 240,000 securities outstanding.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44703305/bitcoin-is-a-more-liquid-and-higher-volatility-version-of-gold-bernstein">Bitcoin Is A &#8216;More Liquid And Higher Volatility Version Of Gold&#8217;: Bernstein</a>
Why It Matters: Dogecoin, launched in 2013 as a lighthearted take on cryptocurrencies inspired by the viral &#8220;Doge&#8221; meme, has since grown into a recognized global payments solution.
The currency's accessibility and loyal user base have helped transform it from a cultural phenomenon into a practical gateway for crypto adoption.
21Shares' listing provides investors with a structured and regulated way to gain exposure to Dogecoin without having to directly purchase or manage the token via a crypto wallet. 
This approach is increasingly popular among traditional investors looking for simplified access to digital assets.
Dogecoin's growth has also been propelled by a strong, socially-driven community known for charitable initiatives and open participation. 
Community-led campaigns such as Doge4Water, which raised funds in 2014 to provide clean water infrastructure in Kenya, reflect the grassroots ethos behind the token.
The 21Shares Dogecoin ETP launch marks another step in the maturation of meme-driven cryptocurrencies into investable financial instruments, as regulators and traditional institutions respond to continued demand for accessible crypto investment vehicles.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44696653/how-bitcoin-will-go-from-65000-to-225000-in-2025">How Bitcoin Will Go From $65,000 To $225,000 In 2025</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

MSFT

21Shares Launches Dogecoin Fund Backed By Dogecoin Foundation

Morgan Stanley analyst Brian Wilczynski initiates coverage on Atlantic Union Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUB#NYSE">AUB</a>) with a Equal-Weight rating and announces Price Target of $32.

Price Target

Initiation

Analyst Ratings

Morgan Stanley Initiates Coverage On Atlantic Union Bankshares with Equal-Weight Rating, Announces Price Target of $32

Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy and maintains $125 price target.

Reiteration

TTAN

Needham Reiterates Buy on ServiceTitan, Maintains $125 Price Target

Evercore ISI Group analyst Elizabeth Anderson downgrades Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) from Outperform to In-Line and lowers the price target from $6 to $4.

Downgrades

HCAT

Evercore ISI Group Downgrades Health Catalyst to In-Line, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Buy and maintains $40 price target.

RNAC

HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

BMO Capital analyst John McNulty maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Outperform and lowers the price target from $154 to $126.

BMO Capital Maintains Outperform on RPM Intl, Lowers Price Target to $126

Baird analyst Ghansham Panjabi maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Neutral and lowers the price target from $125 to $110.

Baird Maintains Neutral on RPM Intl, Lowers Price Target to $110

Piper Sandler analyst Mike Lavery upgrades Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) from Neutral to Overweight and raises the price target from $35 to $40.

Upgrades

Piper Sandler Upgrades Keurig Dr Pepper to Overweight, Raises Price Target to $40

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on <a href="https://in.benzinga.com/markets/25/04/44627820/trumps-reciprocal-tariffs-on-india-exempt-pharma-easing-mark-cubans-price-hike-concerns">pharmaceuticals imported from foreign countries.</a>
What Happened: President Trump, on Tuesday, disclosed plans for a &#8220;major tariff&#8221; on foreign pharmaceuticals. Trump is hopeful that this move will prompt drug companies to shift their operations to the U.S., <a href="https://www.theguardian.com/australia-news/2025/apr/09/donald-trump-flags-major-tariff-on-pharmaceuticals-as-us-senator-criticises-whack-on-australia">reported</a> The Guardian.
&#8220;We&#8217;re going to be announcing very shortly a major tariff on pharmaceuticals&#8230; when they hear that they will leave China, they will leave other places because&#8230; most of their product is sold here,&#8221; Trump expressed at a National Republican Congressional Committee dinner.
Despite exempting pharmaceuticals from the recent round of reciprocal tariffs, Trump has been hinting for a long time that the drug industry would be a target. The President is of the view that the tariff will drive drug companies to return to the U.S., considering it is a significant market for their products. &#8220;The advantage we have over everybody is that we&#8217;re the big market. So we&#8217;re going to be announcing very shortly a major tariff on pharmaceuticals,&#8221; Trump added.
The President, however, did not divulge any specifics regarding the tariff increase or its potential impact.
Pharmaceutical stocks across the globe, including GlaxoSmithKline, Sanofi and India&#8217;s Teva Pharmaceuticals, tumbled on Wednesday.
In the U.S. pharmaceutical stocks, Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) declined 3.5%, while Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) lost 3.2%. AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell 1.35%, while Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) dropped 2.94% and 2.75%, respectively, during the Wednesday pre-market trading session.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/04/44706492/trump-predicts-tremendous-thundering-landslide-in-2026-midterms-says-tariffs-will-help-republicans-win-bi" target="_blank" rel="noreferrer noopener">Trump Predicts &#8216;Tremendous, Thundering Landslide&#8217; In 2026 Midterms, Says Tariffs Will Help Republicans Win Big</a>
Why It Matters: The $1.7 trillion revenue prescription drug industry has demonstrated a strong resilience to tariffs. The U.S., being the largest and most profitable market globally for prescription drugs and generic products, imports most of these from overseas. In 2024, drug imports reached $213 billion, more than two and a half times the total 10 years earlier. The proposed tariff could, in theory, help bring business back onshore.
However, companies like&nbsp;AstraZeneca Plc and&nbsp;Pfizer&nbsp;have extensive global manufacturing networks, including Ireland, Germany, Canada, the UK, and the U.S and are not restricted to India and China. Sources told Reuters that it could take up to 10 years to build and equip a factory in the U.S., due to stringent regulatory requirements from the U.S. Food and Drug Administration (FDA). Therefore, Trump&#8217;s tariff might necessitate drugmakers to overhaul a complex, expensive manufacturing system.
Meanwhile, after Trump indicated major tariffs on pharmaceuticals, EU drugmakers have urged European Commission President Ursula von der Leyen to take "rapid and radical action" to address the growing "risk of an exodus" to the U.S., following a meeting in Brussels.
<ul>
<li>READ MORE: <a href="https://benzinga.com/25/04/44705972/ford-motor-general-motors-to-witness-higher-demand-as-american-automotives-reap-the-fruit-of-protectionism-says-e" target="_blank" rel="noreferrer noopener">Ford, GM To Witness &#8216;Higher Demand&#8217; As American Carmakers Set To &#8216;Reap The Fruit Of Protectionism,&#8217; Says Expert: Here&#8217;s A List Of Potential Gainers And Losers From Trump Tariffs</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AMGN

Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market

HC Wainwright &amp; Co. analyst Mitchell Kapoor downgrades Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) from Buy to Neutral.

RLYB

HC Wainwright & Co. Downgrades Rallybio to Neutral

Ancora Holdings, A Stockholder Of United States Steel, Announced That It Is Withdrawing Its Nomination Of Director Candidates For Election At The 2025 Annual Meeting Of Stockholders Due To Apparent Momentum Related To The $55 Per Share Sale To Nippon Steel Corporation

Piper Sandler analyst Korinne Wolfmeyer upgrades Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from Neutral to Overweight and lowers the price target from $38 to $35.

BBWI

Piper Sandler Upgrades Bath & Body Works to Overweight, Lowers Price Target to $35

Theratechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) reported quarterly earnings of $0.00 per share which missed the analyst consensus estimate of $0.01 by 90 percent. This is a 101 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $19.05 million which missed the analyst consensus estimate of $19.62 million by 2.90 percent. This is a 17.23 percent increase over sales of $16.25 million the same period last year.

Earnings

THTX

Theratechnologies Q1 2025 GAAP EPS $0.00 Misses $0.01 Estimate, Sales $19.05M Miss $19.62M Estimate

SOBO

South Bow Disclosed Has Shut Down The Keystone Pipeline (Keystone) And Is Actively Responding To An Oil Release At Milepost 171 (MP-171) Of Keystone, Near Fort Ransom, North Dakota

CNTX

Context Therapeutics Announced That The First Patient Has Been Dosed In The Phase 1 Clinical Trial Of CT-95, A Mesothelin (MSLN) X CD3T Cell Engaging (TCE) Bispecific Antibody Designed To Target Mesothelin-expressing Cancers

Mizuho analyst Ravi Vaidya initiates coverage on CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) with a Neutral rating and announces Price Target of $39.

CUBE

Mizuho Initiates Coverage On CubeSmart with Neutral Rating, Announces Price Target of $39

Contracts

Teledyne FLIR Defense Announced It Has Been Awarded A Four Year, $74.2M Contract By The U.S. Army For Next-gen Nuclear, Biological And Chemical Reconnaissance Vehicle Sensor Suite Upgrade

Mizuho analyst Ravi Vaidya initiates coverage on Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Neutral rating and announces Price Target of $287.

Mizuho Initiates Coverage On Public Storage with Neutral Rating, Announces Price Target of $287

Mizuho analyst Ravi Vaidya initiates coverage on Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) with a Outperform rating and announces Price Target of $141.

Mizuho Initiates Coverage On Extra Space Storage with Outperform Rating, Announces Price Target of $141

Mizuho analyst Ravi Vaidya initiates coverage on National Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSA#NYSE">NSA</a>) with a Neutral rating and announces Price Target of $35.

Mizuho Initiates Coverage On National Storage with Neutral Rating, Announces Price Target of $35

Press Releases

Piper Sandler Strengthens Financial Services Group with the Addition of Matt Somma

RED ROBIN GOURMET BURGERS, INC. ANNOUNCES INVESTMENT AND APPOINTS NEW INDEPENDENT DIRECTORS

Piper Sandler Expands Healthcare Investment Banking Team with the Addition of John Kerins

Piper Sandler Companies to Announce Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call on January 31, 2025

Piper Sandler Companies Reports Fourth Quarter and Full Year 2024 Results; Declares Special Dividend of $3.00 Per Share and Quarterly Dividend of $0.65 Per Share

Piper Sandler Companies Announces Share Repurchase Authorization

Piper Sandler Expands Private Capital Advisory Group with Three Key Hires

Piper Sandler Strengthens Fixed Income Team with the Addition of Mary Stone

Piper Sandler Expands Research Distribution with New Office Opening in Zurich

Piper Sandler Expands Healthcare Investment Banking Team with the Addition of Christian Draisbach

IVFH

RRGB

UNFI

BGC Group

Evercore

Freedom Holding

Futu Holdings Limited - American Depositary Shares

Futu Hldgs

Goldman Sachs Group, Inc. (The) Common Stock

Goldman Sachs Group

Houlihan Lokey, Inc. Class A Common Stock

Houlihan Lokey

Robinhood Markets, Inc. - Class A Common Stock

Robinhood Markets

Interactive Brokers Group, Inc. - Class A Common Stock

Interactive Brokers Group

Jefferies Financial Group Inc. Common Stock

Jefferies Financial Gr

Lazard

LPL Financial Holdings Inc. - Common Stock

LPL Finl Hldgs

Moelis

Marex Group

Morgan Stanley

Nomura Holdings Inc ADR American Depositary Shares

Nomura Holdings

Oppenheimer Holdings, Inc. Class A Common Stock (DE)

Oppenheimer Hldgs

PJT Partners

Perella Weinberg Partners - Class A Common Stock

Perella Weinberg

Raymond James Financial, Inc. Common Stock

Raymond James Finl

Charles Schwab Corporation (The) Common Stock

Charles Schwab

Stifel Financial Corporation Common Stock

Stifel Financial

StoneX Group

UP Fintech Holding Limited - American Depositary Shares representing fifteen Class A Ordinary Shares

Comments

Piper Sandler

Notizie

Ultime notizie per Piper Sandler (NYSE:PIPR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO